Clinical trials: sponsored by Zhejiang Cancer Hospital
Breast Cancer
Research on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC Therapy
This study aims to develop an AI-based predictive tool to help clinicians more accurately determine whether breast cancer patients can benefit from HER-2-targeted antibody-drug conjugate (T-DXd) therapy before treatment.
- Trial name
- NCT07689929
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer, Stage IV Breast Cancer
Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone Metastases
This is a national multicenter, prospective, randomized controlled trial. The study aims to compare the 5-year overall survival (OS) between patients receiving primary tumor surgery followed by systemic therapy (surgery group)…
- Conditions
- Breast Cancer, Stage IV Breast Cancer, Bone Metastases
- Trial name
- POSITIVE-Bone (NCT07687225)
- Testing
- Primary Tumor Resection, Standard systemic therapy
- Volunteers
- 216 people
- Sponsor
- West China Hospital
Cervical Cancer, Recurrent Cervical Cancer
Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer
Primary Objective of this study: To investigate the correlation between longitudinal quantitative dynamics of circulating tumor DNA (ctDNA) and HPV-derived cell-free DNA (HPV cfDNA) in peripheral blood and clinical prognosis…
- Conditions
- Cervical Cancer, Recurrent Cervical Cancer, Metastatic Cervical Cancer
- Trial name
- NCT07673211
- Testing
- Biospecimen collection (peripheral blood and paraffin tumor tissue)
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Hematological Malignancies B
Biodistribution, Dosimetry, and Safety of 68Ga-EV203 in Hematological Malignancies
The goal of this clinical trial is to evaluate the biodistribution, radiation dosimetry, safety, and time-dependent image quality of ^68^Ga-EV203 injection in patients with hematological malignancies (multiple myeloma…
- Trial name
- NCT07670949
- Testing
- 68Ga-EV203 PET/CT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Malignant Tumor
Establishment of Tongue Image Database and Machine Learning Model for Malignant Tumors Diagnosis
The tongue images of malignant tumors and corresponding healthy people will be collected to establish the tongue image database.
- Trial name
- NCT04793672
- Testing
- Tongue images, coating on the tongue and clinical data of patients with malignant tumors and healthy people will be collected.
- Where
- 2 sites in China
- Volunteers
- 4,100 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Rectal Cancer
SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak
The goal of this clinical trial is to learn whether using a reinforcing material called SIS (small intestinal submucosa) during bowel connection after rectal cancer surgery can help prevent anastomotic leakage-a serious…
- Trial name
- NCT07209787
- Testing
- SIS-reinforced anastomosis
- Where
- China
- Volunteers
- 966 people
- Sponsor
- Beijing Chao Yang Hospital
Esophageal Neoplasms
Effects of Preoperative Enteral Immunonutrition for Esophageal Cancer Patients Given Neoadjuvant Chemoradiotherapy
This randomized controlled trial will evaluate the effects of preoperative enteral immunonutrition in esophageal cancer patients undergoing neoadjuvant therapy.
- Trial name
- POINT (NCT04513418)
- Testing
- Preoperative immunonutrition
- Where
- 6 sites in China
- Volunteers
- 244 people
- Sponsor
- Hecheng Li M.D., Ph.D
Ovarian Cancer (OvCa)
Rectosigmoid Lesion Excision vs. Resection: A Non-Inferiority Randomized Comparison in Advanced Ovarian Cancer
Colorectum is the most common site of metastasis in ovarian cancer. Regarding intestinal surgery, there is controversy over whether to choose bowel resection or tumor removal, and currently, there are no prospective randomized…
- Trial name
- RSEnTrail (NCT07616310)
- Testing
- Rectosigmoid Lesion Excision +tumor cell debulking surgery, Rectosigmoid Resection +tumor cell debulking surgery
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Carcinoma, Small Cell, Lung Neoplasms
Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC
The purpose of this study is to determine whether hypofractionated concurrent chemo-radiotherapy has the same efficiency as conventionally fractionated concurrent chemo-radiotherapy in Limited Disease Small Cell Lung Cancer.
- Trial name
- NCT02688036
- Testing
- hypofractionated concurrent chemoradiotherapy, conventionally fractionated concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 860 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced Gastric or Gastroesophageal Junction Cancer
A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer
The objective of the study is to evaluate Tolerability, Safety, and primary Efficacy of Gentuximab Injection at different dosage in combination with Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer patients, to…
- Trial name
- NCT04053205
- Testing
- Gentuximab, Paclitaxel
- Where
- 12 sites in China
- Volunteers
- 76 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Ovarian Clear Cell Carcinoma
INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma
The goal of this phase 3 clinical trial is to evaluate whether QL1706 plus bevacizumab can effectively treat adult female patients (18 to <75 years old) with newly diagnosed FIGO stage IC-IV ovarian clear cell carcinoma.
- Trial name
- INVIGORATE (NCT07002346)
- Testing
- QL1706 (bispecific antibody targeting PD-1 and CTLA-4), Bevacizumab, carboplatin
- Where
- China
- Volunteers
- 226 people
- Sponsor
- Tongji Hospital
Ovarian Cancer (OvCa)
A Prospective Observational Study of Senaparib in the Treatment of Epithelial Ovarian Cancer
Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors, and the mortality rate ranks the first in…
- Trial name
- RESO (NCT07586449)
- Testing
- Senaparib capsules(20mg)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Zhejiang Cancer Hospital
High-risk R/R LBCL
CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.
This is a prospective, single-arm, single-center, open-label clinical study, aiming to evaluate the efficacy and safety of CAR-T combined with ASCT in the treatment of relapsed/refractory large B-cell lymphoma with high-risk…
- Trial name
- CAR-T+ASCT (NCT07538635)
- Testing
- Axicabtagene Ciloleucel
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma, Radiotherapy; Complications
Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma
This is a multi-center, non-inferiority, open-label, randomized controlled phase III clinical trial in primary diagnosed nasopharyngeal carcinoma (NPC) patients without distant metastasis.
- Trial name
- NCT05780372
- Testing
- Intensity Modulated Radiation Therapy, Chemotherapy
- Where
- 7 sites in China
- Volunteers
- 474 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Nutrition Therapy
Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition
This is a multicenter, randomized controlled, phase III clinical trial. The purpose of this study is to evaluate the efficacy of standard nutrition treatment versus conventional nutrition treatment in local advanced…
- Trial name
- NCT04436965
- Testing
- Standardized nutrition therapy, Cisplatin, Intensity Modulated Radiation Therapy
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Sun Yat-sen University
MALT Lymphoma
Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma
This is a prospective, multicenter Phase 2 clinical trial named the MALT-RO study, evaluating ultra-low-dose radiation therapy followed by orelabrutinib as first-line treatment for adults with Stage I-II MALT lymphoma.
- Trial name
- NCT07554898
- Testing
- Orelabrutinib, Ultra-low-dose Radiation Therapy
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of EGFR antibody combined with programmed death 1 (PD-1) antibody and chemotherapy in…
- Conditions
- Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma, Metastatic Nasopharyngeal Carcinoma
- Trial name
- NCT06802835
- Testing
- EGFR Antibody, PD-1 antibody, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis
Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
To explore the efficacy of Houyanqing Oral Liquid combined with conventional treatment in preventing and treating radiation-induced oral mucositis, so as to improve the quality of life of nasopharyngeal carcinoma patients…
- Trial name
- NCT07311772
- Testing
- Houyanqing Oral Liquid, Conventional Treatment for Radiation-Induced Oral Mucositis
- Where
- 16 sites in China
- Volunteers
- 386 people
- Sponsor
- Sun Yat-sen University
Invasive Fungal Disease, Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Longitudinal Cohort Study on Invasive Fungal Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Invasive fungal disease (IFD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), characterized by high incidence and high mortality.
- Trial name
- NCT07569055
- Where
- China
- Volunteers
- 6,000 people
- Sponsor
- Peking University People's Hospital
Non-Small Cell Lung Cancer
Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation
This is a prospective, single-arm, multicenter, phase II study to investigate the efficacy and safety of Ensartinib plus Bevacizumab in metastatic anaplastic lymphoma kinase (ALK)-rearranged Non-Small Cell Lung Cancer (NSCLC)…
- Trial name
- EAGLE (NCT05491811)
- Testing
- Ensartinib, Bevacizumab
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University